Lyell Immunopharma, Inc.
HealthcareNASDAQ:LYEL · NASDAQ Global Select
-$0.22 today
Vol 0.09M · Avg 0.09M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-110.6%
avg -49.3%
ROIC
-70.1%
avg -38.5%
ROA
-80.7%
avg -38.5%
Analysis
ROIC is currently the strongest return metric at -70.1% versus its period average of -38.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Lynn Seely | Principal Executive Officer, President, CEO & Director | $1.13M | — | 67 | $74,266.00 | 0.32% |
Stephen J. Hill | Chief Operating Officer | $830,564.00 | — | 55 | $17,795.00 | 0.08% |
Gary Lee | Chief Scientific Officer | $786,805.00 | — | 49 | $16,938.00 | 0.07% |
Richard D. Klausner | Founder & Executive Chairman | $85,000.00 | — | 74 | $9,250.00 | 0.04% |
Mark A. Meltz | General Counsel & Corporate Secretary | — | — | 52 | $9,250.00 | 0.04% |
Jarrad Aguirre | Senior Vice President of Medical Affairs | — | — | — | — | — |
Bryan Selby | Senior Vice President of Clinical Development Operations | — | — | — | — | — |
Smital Shah | Principal Financial Officer, CFO & Chief Business Officer | — | — | 50 | $140,000.00 | 0.60% |
Veronica Sanchez Bulis | VP, Corporate Controller, Principal Accounting Officer | — | — | 48 | $15,891.00 | 0.07% |
Nellie Dillery | Director of Accounting | — | — | — | — | — |
Ann Tomlin | Chief Human Resources Officer | — | — | — | — | — |
Crystal L. Mackall | Founder & Scientific Advisor | — | — | 65 | — | — |
Stanley R. Riddell | Founder & Scientific Advisor | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$25.00M
Sells
26
$511,258.69
Net Sentiment
+$24.49M
Net buying
Most Active
Lee Gary K.
6 transactions
1–10 of 28
Analysis
Insiders reported 2 buys worth $25.00M and 26 sells worth $511,258.69 over the last 12 months. That adds up to net buying of $24.49M. Lee Gary K. was the most active insider with 6 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -74.4% | +199.3% (7yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at -74.4% over three years. Forward estimates point to Revenue at +199.3% (7yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Cabaletta Bio, Inc.
NASDAQ:CABA
$490.79M
Allogene Therapeutics, Inc.
NASDAQ:ALLO
$463.35M
Kyverna Therapeutics, Inc.
NASDAQ:KYTX
$352.74M
Silence Therapeutics plc
NASDAQ:SLN
$316.00M
Amarin Corporation plc
NASDAQ:AMRN
$315.21M
Larimar Therapeutics, Inc.
NASDAQ:LRMR
$296.96M
Editas Medicine, Inc.
NASDAQ:EDIT
$244.75M
AC Immune S.A.
NASDAQ:ACIU
$235.10M
Genelux Corporation
NASDAQ:GNLX
$111.35M
Aldeyra Therapeutics, Inc.
NASDAQ:ALDX
$106.17M
Who manages LYEL?
Lyell Immunopharma, Inc. (LYEL) lists 13 active executives. The top listed executive is Mark A. Meltz, General Counsel & Corporate Secretary.
Are LYEL insiders buying or selling?
Recent insider activity shows net buying of $76.47M.
Explore More
Continue the stock analysis
Jump to another research area for this company.